14th Jan 2025 12:07
Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in China for adult patients. It has been developed in collaboration with AstraZeneca PLC, with Hutchmed leading in China and AZ leading outside of China. The drug was approved by the China National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. The approval was based on data from the confirmatory phase 3B clinical trial.
Hutchmed Chief Medical Officer Michael Shi said: "The approval marks an exciting step forward in addressing the unmet needs of NSCLC patients with MET exon 14 skipping alteration. It not only validates our research but also emphasizes our dedication to addressing unmet medical needs through targeted drug development."
Current stock price: 247.00 pence, up 2.1%
12-month change: down 1.8%
By Michael Hennessey, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.